Clinical Trials Logo

Clinical Trial Summary

Obesity is closely associated with an increased risk of cardiomyopathy because of the high metabolic activity of excessive fat while effective treatment of obesity-related cardiomyopathy is currently unsolved. Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) are a class of diabetic medications. Besides improving glucose control, SGLT2-i has been shown to be able to reduce the bodyweight as well as the mortality and hospitalization rates for heart failure and cardiovascular disease in the type 2 diabetes patients. It has been proposed that the heart protection by SGLT2-i might be caused by modulating the production of adipokine and cytokine. The investigators will enrolled 40 patients (diabetes mellitus with BMI>27 Kg/m2) from obesity weight-reduction clinics: 1) 20 patients treated with SGLT2-i (CANA) and regular weight-reduction plan; 2) 20 patients with regular weight reduction plan, without CANA, for 4 weeks. The investigators will compare the variation of Fibroblast growth factor-21 (FGF21) related proteins and RNA between these 2 groups of subjects. The investigators will arrange cardiac ultrasound, hepatic MRI and fibroscan, body composition dual energy x-ray absorptiometry to evaluate the possible mechanisms underlying the liver and heart modification process, as a scientific basis for precision medicine in the future. Conclusions: SGLT2-i treatment may increase the concentration of FGF21, either in the liver or heart, thus to protect the high-fat diet induced obesity associated heart dysfunction by activating FGF21 downstream protein expression.


Clinical Trial Description

The investigators will enrolled 40 diabetes mellitus with BMI>27 Kg/m2 patients from obesity weight-reduction clinics and will compare the variation of FGF21 related proteins between these 2 groups of subjects. Serial examinations will evaluate the possible mechanisms underlying the protective mechanism. This investigation expect that SGLT2-inhibitor can increase the concentration of FGF21 in the heart by increasing FGF21 in the liver, thereby modifying associated protein expressions and ultimately improving cardiac function and patient outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05764811
Study type Interventional
Source National Cheng-Kung University Hospital
Contact
Status Completed
Phase N/A
Start date March 6, 2020
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05881005 - NAC- NAFLD And Cushing N/A
Recruiting NCT05220956 - Impact of Time-restricted Feeding in NAFLD N/A
Enrolling by invitation NCT04066608 - Prevalence of Advanced Fibrosis in Patients Living With HIV
Recruiting NCT04302051 - Assessment of Fatty Liver With Thermo-acoustic Device
Recruiting NCT04496895 - The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults N/A
Recruiting NCT05880316 - Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting N/A
Active, not recruiting NCT05898841 - Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load Phase 4
Active, not recruiting NCT05076058 - Effects of Tablets of Silybum Marianum, Pueraria Lobate and Salvia Miltiorrhiza on Fatty Liver N/A
Recruiting NCT05421572 - Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Recruiting NCT06302049 - Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis Phase 1/Phase 2
Completed NCT04283942 - Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism N/A
Completed NCT01016418 - Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease Phase 1/Phase 2
Terminated NCT04175392 - Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis Phase 1/Phase 2
Not yet recruiting NCT04191044 - Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)
Not yet recruiting NCT06071923 - Effect of Thyroid Disorders in Liver Diseases
Recruiting NCT04525833 - Liver Disease and Other Systemic Diseases
Not yet recruiting NCT05966025 - Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD) Phase 2
Completed NCT04844450 - A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795 Phase 1
Completed NCT04367012 - Fatty Liver Among Employees at Banha University
Completed NCT05694923 - Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients N/A